CURRENT MEDICATIONS OVERVIEW,,
MEDICATION,GENE(S),PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST
"Melatonin",CYP1A2,"Minor – result should be considered as may affect medicationresponse"
"Paroxetine",CYP2D6,Usual prescribing considerations apply
MEDICATIONS THAT DO NOT HAVE PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST,,
"latanoprost, budesonide / eformoterol fumarate dihydrate (Symbicort Turbuhaler), clonazepam",,
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Angiotensin receptorblockers",Losartan,CYP2C9,Reduced / inadequate response,-
Anticoagulants,Acenocoumarol,"VKORC1CYP2C9","Significantly increasedacenocoumarol sensitivity",DPWG
Warfarin,"VKORC1CYP2C9","Significantly increased warfarinsensitivity",FDA3,
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Antidiabetics,Glimepiride,CYP2C9,"Increased therapeutic and/oradverse effects",-
"",Glyburide,CYP2C9,"Increased therapeutic and/oradverse effects",-
Antiepileptics,Phenytoin,CYP2C9,Adverse effects,CPIC4
NSAIDs,Celecoxib,CYP2C9,"Increased therapeutic and/oradverse effects",FDA5
"",Flurbiprofen,CYP2C9,Adverse effects,"FDA6,7"
"",Ibuprofen,CYP2C9,Adverse effects,-
"",Meloxicam,CYP2C9,Adverse effects,-
"",Piroxicam,CYP2C9,Adverse effects,-
Statins,Fluvastatin,"SLCO1B1CYP2C9","Increased therapeutic and/oradverse effects",-
Simvastatin,"SLCO1B1CYP3A4",Adverse effects,CPIC8,
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Angiotensin receptorblockers",Irbesartan,CYP2C9,"Increased therapeutic and/oradverse effects",-
"Antidepressants -other",Mirtazapine,"CYP2D6CYP1A2",Reduced / inadequate response,-
"Antidepressants -serotoninnoradrenalinereuptake inhibitors",Duloxetine,"CYP2D6CYP1A2",Reduced / inadequate response,-
"Antidepressants -SSRIs",Fluoxetine,"CYP2D6CYP2C9",Altered response,-
Antidiabetics,Gliclazide,"CYP2C9CYP2C19","Increased therapeutic and/oradverse effects",-
Antipsychotics,Clozapine,CYP1A2,Reduced / inadequate response,-
"",Olanzapine,CYP1A2,Reduced / inadequate response,-
Beta blockers,Propranolol,"CYP2D6CYP1A2",Altered response,-
Hypnotics,Melatonin,CYP1A2,Reduced / inadequate response,-
Miscellaneous,Naltrexone,OPRM1,"Associated with reducedresponse to naltrexone",
NSAIDs,Diclofenac,CYP2C9,Adverse effects,-
"",Indomethacin,CYP2C9,Adverse effects,-
"",Mefenamic Acid,CYP2C9,Adverse effects,-
Opioid Analgesics,Morphine,OPRM1,"Associated with increasedtherapeutic and/or adverseeffects to morphine",-
"Proton pumpinhibitors",Dexlansoprazole,CYP2C19,Reduced / inadequate response,-
"",Esomeprazole,CYP2C19,Reduced / inadequate response,-
"",Lansoprazole,CYP2C19,Reduced / inadequate response,-
"",Omeprazole,CYP2C19,Reduced / inadequate response,-
"",Pantoprazole,CYP2C19,Reduced / inadequate response,-
"",Rabeprazole,CYP2C19,Reduced / inadequate response,-
Statins,Atorvastatin,"SLCO1B1CYP3A4",Adverse effects,-
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"ADHD -miscellaneous agents",Atomoxetine,CYP2D6,"No altered effect predicted bygenotype",-
Antiarrhythmics,Flecainide,CYP2D6,"No altered effect predicted bygenotype",-
"",Propafenone,CYP2D6,"No altered effect predicted bygenotype",-
"Anticholinergics(genitourinary)",Darifenacin,CYP2D6,"No altered effect predicted bygenotype",-
"",Fesoterodine,CYP2D6,"No altered effect predicted bygenotype",-
"",Tolterodine,CYP2D6,"No altered effect predicted bygenotype",-
Anticholinesterases,Donepezil,CYP2D6,"No altered effect predicted bygenotype",-
"",Galantamine,CYP2D6,"No altered effect predicted bygenotype",-
"Antidepressants -other",Moclobemide,CYP2C19,"No altered effect predicted bygenotype",-
"",Vortioxetine,CYP2D6,"No altered effect predicted bygenotype",-
"Antidepressants -serotoninnoradrenalinereuptake inhibitors",Venlafaxine,CYP2D6,"No altered effect predicted bygenotype",DPWG9
"Antidepressants -SSRIs",Citalopram,CYP2C19,"No altered effect predicted bygenotype",CPIC2
"",Escitalopram,CYP2C19,"No altered effect predicted bygenotype",CPIC2
"",Fluvoxamine,"CYP2D6CYP1A2","No altered effect predicted bygenotype",CPIC2
"",Paroxetine,CYP2D6,"No altered effect predicted bygenotype",CPIC2
"",Sertraline,CYP2C19,"No altered effect predicted bygenotype",CPIC2
"Antidepressants -tricyclicantidepressants",Amitriptyline,"CYP2D6CYP2C19","No altered effect predicted bygenotype",CPIC10
"",Clomipramine,"CYP2D6CYP2C19","No altered effect predicted bygenotype",CPIC10
"",Desipramine,CYP2D6,"No altered effect predicted bygenotype",CPIC10
"",Doxepin,"CYP2D6CYP2C19","No altered effect predicted bygenotype",CPIC10
"",Imipramine,"CYP2D6CYP2C19","No altered effect predicted bygenotype",CPIC10
"",Nortriptyline,CYP2D6,"No altered effect predicted bygenotype",CPIC10
Antiemetics,Metoclopramide,CYP2D6,"No altered effect predicted bygenotype",-
"",Ondansetron,CYP2D6,"No altered effect predicted bygenotype",CPIC11
Antifungals - Azoles,Voriconazole,CYP2C19,"No altered effect predicted bygenotype",CPIC12
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Antihistamines,Chlorpheniramine,CYP2D6,"No altered effect predicted bygenotype",-
"",Dexchlorpheniramine,CYP2D6,"No altered effect predicted bygenotype",-
"",Promethazine,CYP2D6,"No altered effect predicted bygenotype",-
Antiplatelet drugs,Clopidogrel,CYP2C19,"No altered effect predicted bygenotype",CPIC13
Antipsychotics,Aripiprazole,CYP2D6,"No altered effect predicted bygenotype",-
"",Brexpiprazole,CYP2D6,"No altered effect predicted bygenotype",-
"",Chlorpromazine,CYP2D6,"No altered effect predicted bygenotype",-
"",Haloperidol,CYP2D6,"No altered effect predicted bygenotype",-
"",Pimozide,CYP2D6,"No altered effect predicted bygenotype",
"",Quetiapine,CYP3A4,"No altered effect predicted bygenotype",-
"",Risperidone,CYP2D6,"No altered effect predicted bygenotype",-
"",Zuclopenthixol,CYP2D6,"No altered effect predicted bygenotype",-
Antitussives,Dextromethorphan,CYP2D6,"No altered effect predicted bygenotype",-
Benzodiazepines,Clobazam,CYP2C19,"No altered effect predicted bygenotype",-
"",Diazepam,CYP2C19,"No altered effect predicted bygenotype",-
Beta blockers,Carvedilol,CYP2D6,"No altered effect predicted bygenotype",-
"",Metoprolol,CYP2D6,"No altered effect predicted bygenotype",-
"",Nebivolol,CYP2D6,"No altered effect predicted bygenotype",-
Calcineurin inhibitors,Tacrolimus,CYP3A5,"No altered effect predicted bygenotype",CPIC14
"Glaucoma - ocularpreparations",Timolol,CYP2D6,"No altered effect predicted bygenotype",-
"Immunomodulatorsand antineoplastics",Tamoxifen,CYP2D6,"No altered effect predicted bygenotype",CPIC15
Miscellaneous,Atazanavir,CYP3A5,"No altered effect predicted bygenotype",-
"",Cyclophosphamide,CYP2C19,"No altered effect predicted bygenotype",-
"",Eliglustat,CYP2D6,"No altered effect predicted bygenotype",TGA16
"",Proguanil,CYP2C19,"No altered effect predicted bygenotype",-
Neurological drugs,Tetrabenazine,CYP2D6,"No altered effect predicted bygenotype",FDA17
Opioid Analgesics,Codeine,"CYP2D6OPRM1","Associated with increasedsensitivity to codeine",CPIC18
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"",Hydrocodone,CYP2D6,"No altered effect predicted bygenotype",
"",Oxycodone,CYP2D6,"No altered effect predicted bygenotype",-
"",Tramadol,CYP2D6,"No altered effect predicted bygenotype",-
Psychostimulants,Dextroamphetamine,CYP2D6,"No altered effect predicted bygenotype",-
"",Lisdexamfetamine,CYP2D6,"No altered effect predicted bygenotype",-
Statins,Pravastatin,SLCO1B1,"No altered effect predicted bygenotype",-
Rosuvastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
